Shares of Solid Biosciences (NASDAQ:SLDB) jumped ~86% in the premarket on Tuesday after the gene therapy developer reported promising early results from a Phase 1/2 trial for its lead asset SGT-003 in Duchenne muscular dystrophy, a genetically driven muscle disorder.

SGT-003 is designed to deliver a microdystrophin gene that instructs cells to make functional versions of the dystrophin protein, the synthesis of which gets impacted in Duchenne muscular dystrophy.

Citing 90-day biopsy data from its INSPIRE DUCHENNE trial, the Charlestown, Massachusetts-based Solid Bio (NASDAQ:SLDB) said the first three participants in the study witnessed an average microdystrophin expression of 110%.

The company also cited significant improvements in other additional muscle health biomarkers and indicated a well-tolerated safety profile for its experimental therapy with no serious adverse events seen in six patients as of Feb. 11, 2025.

Solid Bio (NASDAQ:SLDB) expects to dose about 20 patients by Q4 2025 with SGT-003 and engage with the FDA in mid-2025 to seek a potential accelerated approval pathway for the drug.

Concurrently, the company announced the pricing of an equity offering indicating a per share share price of $4.03 for more than 35.7M shares of its common stock. An offering of warrants to purchase over 13.8M shares of common stock was also priced at $4.029 apiece.

The company projects about $200M in gross proceeds from the equity offering, which is expected to close on Wednesday.